cTAGE1: A Protein Involved in DNA Damage Response and Drug Detoxification

Target Name: CTAGE1

NCBI ID: G64693

CTAGE1

cTAGE1: A Protein Involved in DNA Damage Response and Drug Detoxification

CTAGE1 (cTAGE family member 2) is a protein that is expressed in various tissues throughout the body. It is a member of the cTAGE family, which is a group of proteins that are involved in the detoxification of xenobiotics, such as drugs and other harmful substances. cTAGE1 is also known as Nrf2, and it is a key regulator of the DNA damage response.

The DNA damage response is a critical process that helps the body repair damage to its DNA. When the DNA is damaged, the cell goes into a state of stress, and the DNA damage response is triggered to repair the damage and restore the cell to its normal state. cTAGE1 is involved in this process by regulating the expression of genes that are involved in the DNA damage response.

One of the functions of cTAGE1 is to detoxify drugs. Many drugs are toxic to the body, and they can cause damage to the DNA. cTAGE1 helps to protect the body's DNA by detoxifying these drugs before they have a chance to cause damage. This is accomplished by cTAGE1 activating the detoxification pathways that are involved in the detoxification of drugs.

Another function of cTAGE1 is to regulate the expression of genes that are involved in cell signaling. Many diseases are caused by the misregulation of cell signaling, and cTAGE1 helps to ensure that these signaling pathways are properly regulated. This is accomplished by cTAGE1 activating the negative signaling pathways that are involved in the regulation of cell signaling.

In addition to its functions in detoxification and cell signaling, cTAGE1 is also involved in the regulation of cellular processes that are important for the survival of the cell. This includes the regulation of cell growth, apoptosis, and the cytoskeleton. cTAGE1 helps to maintain the cell's shape and stability, and it also helps to ensure that the cell dies when it is no longer needed.

The cTAGE1 gene is located on chromosome 6 and it encodes a protein of 21 kDa. It is expressed in various tissues throughout the body, including the liver, spleen, kidney, heart, and brain. cTAGE1 is involved in the detoxification of drugs, cell signaling, and cellular processes that are important for the survival of the cell.

cTAGE1 is also a potential drug target. Many drugs are designed to target specific proteins, and cTAGE1 is one of those proteins. These drugs can include inhibitors of cTAGE1's activity, as well as modulators of its expression. By targeting cTAGE1, these drugs can be used to treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In conclusion, cTAGE1 (cTAGE family member 2) is a protein that is involved in the detoxification of drugs, cell signaling, and cellular processes that are important for the survival of the cell. It is a key regulator of the DNA damage response and it is a potential drug target. Further studies are needed to fully understand the role of cTAGE1 in the body and its potential as a drug.

Protein Name: Cutaneous T Cell Lymphoma-associated Antigen 1

The "CTAGE1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTAGE1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets